Patient-derived xenograft models of prostate tumors

P.J. Russell, E. D. Williams, R. Taylor, M.G. Lawrence, G. Risbridger

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

Abstract

In contrast to many other solid tumor types, the potential of using patient-derived xenografts (PDXs) from prostate cancer for preclinical research has yet to be fully realized. Prostate cancer PDXs are notoriously difficult to establish and this section provides a state-of-the-art summary including the effect of implantation site on revealing metastatic potential and the role of the microenvironment in supporting take rate and model fidelity. Tissue recombination is described as a technique that can improve the take rate of prostate xenografts that span the stages of prostate cancer progression. Comparisons of the pathology and molecular profiles of short- and long-term transplantable xenografts are made to describe their potential for studies of tumor biology and for preclinical applications involving patient-directed/targeted therapies.

Original languageEnglish
Title of host publicationPatient Derived Tumor Xenograft Models: Promise, Potential and Practice
EditorsRajesh Uthamanthil, Peggy Tinkey, Elisa de Stanchina
PublisherElsevier
Pages217-228
Number of pages12
ISBN (Electronic)9780128040614
ISBN (Print)9780128040102
DOIs
Publication statusPublished - 2017

Keywords

  • Humanized
  • Implantation sites: subrenal capsule, subcutaneous, intraprostatic
  • Patient-derived xenografts (PDX)
  • Prostate cancer
  • Stromal precursors
  • Tissue recombination
  • Urogenital mesenchyme

Cite this